Advertisement
Abstract| Volume 45, SUPPLEMENT 2, S172-S174, November 2022

Patient (pt) reported pain and health-related quality of life (HRQoL) by genomic loss of heterozygosity (gLOH) status in men with metastatic castration-resistant prostate cancer (mCRPC) receiving talazoparib (TALA): TALAPRO-1

      This paper is only available as a PDF. To read, Please Download here.